RAS Mutational Detection in Tumors
To detect activating point mutations in the KRAS and NRAS genes, which are commonly present in leukemias with monocytic differentiation (AML, CMML), and in solid tumors such as melanoma, lung cancer and colorectal carcinoma. Presence of KRAS mutations have been shown to confer resistance to anti-EGFR monoclonal antibodies.
This test is performed by PCR-based Pyrosequencing of DNA to examine the mutation status of codons 12 and 13 in exon 2 and codon 61 in exon 3 of KRAS and NRAS.
This assay can detect mutations present in codons 12, 13 and 61 of KRAS and NRAS. The sensitivity of the Pyrosequencing assay is 5-10% of variant sequence in the background of wild-type sequence.
10 mL peripheral blood, 2-5mL bone marrow aspirate, 5g purified DNA, or 4-10 unstained tissue sections on glass slides along with 1 H&E-stained section.
Please provide a copy of the corresponding pathology report.
81275, 81403, 81404
Additional charges may apply for tissue extraction.
The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.